V
Vibeke Strand
Researcher at Stanford University
Publications - 474
Citations - 26064
Vibeke Strand is an academic researcher from Stanford University. The author has contributed to research in topics: Rheumatoid arthritis & Randomized controlled trial. The author has an hindex of 75, co-authored 435 publications receiving 23443 citations. Previous affiliations of Vibeke Strand include University of Toronto & American College of Rheumatology.
Papers
More filters
Journal ArticleDOI
American college of rheumatology preliminary definition of improvement in rheumatoid arthritis
David T. Felson,David T. Felson,Jennifer J. Anderson,Jennifer J. Anderson,Maarten Boers,Claire Bombardier,Claire Bombardier,Daniel E. Furst,Daniel E. Furst,Charles H. Goldsmith,Charles H. Goldsmith,Linda M. Katz,Linda M. Katz,Robert W. Lightfoot,Robert W. Lightfoot,Harold E. Paulus,Harold E. Paulus,Vibeke Strand,Vibeke Strand,Peter Tugwell,Peter Tugwell,Michael E. Weinblatt,Michael E. Weinblatt,H. James Williams,H. James Williams,Frederick Wolfe,Stephanie Kieszak +26 more
TL;DR: The results suggest that the definition of improvement presented is statistically powerful and does not identify a large percentage of placebo-treated patients as being improved, which the authors hope will be used widely in RA trials.
Journal ArticleDOI
American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials
David T. Felson,David T. Felson,Josef S Smolen,George A. Wells,Bi Zhang,Lilian H D van Tuyl,Julia Funovits,Daniel Aletaha,Cornelia F Allaart,Joan M. Bathon,Joan M. Bathon,Stefano Bombardieri,Peter Brooks,Andrew K Brown,Marco Matucci-Cerinic,Hyon K. Choi,Bernard Combe,Maarten de Wit,Maxime Dougados,Paul Emery,Daniel E. Furst,Juan J. Gomez-Reino,Gillian A. Hawker,Edward C. Keystone,Dinesh Khanna,John R. Kirwan,Tore K Kvien,Robert Landewé,Joachim Listing,Kaleb Michaud,Emilio Martín-Mola,Pamela Montie,Theodore Pincus,Pamela Richards,Jeffrey Siegel,Jeffrey Siegel,Lee S. Simon,Tuulikki Sokka,Vibeke Strand,Peter Tugwell,Alan Tyndall,Désirée van der Heijde,S. M. M. Verstappen,Barbara White,Frederick Wolfe,Angela Zink,Maarten Boers +46 more
TL;DR: It is proposed that a patient's RA can be defined as being in remission based on one of two definitions: (1) when scores on the tender joint count, swollen joint counts, CRP level, and patient global assessment are all ≤1, or (2) when the score on the Simplified Disease Activity Index is ≤3.
Journal ArticleDOI
Treatment of Active Rheumatoid Arthritis With Leflunomide Compared With Placebo and Methotrexate
Vibeke Strand,Stanley Cohen,Michael Schiff,Arthur L. Weaver,Roy Fleischmann,Grant W. Cannon,Robert I. Fox,Larry W. Moreland,Nancy J. Olsen,Daniel E. Furst,Jacques Caldwell,Jeffrey L. Kaine,John T. Sharp,Frank Hurley,Iris Loew-Friedrich +14 more
TL;DR: Clinical responses following administration of leflunomide, a new therapeutic agent for the treatment of RA, were statistically superior to those with placebo and equivalent to Those with methotrexate treatment.
Journal Article
Recommendations for a core set of outcome measures for future Phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III
Nicholas Bellamy,John R. Kirwan,Maarten Boers,Peter Brooks,Vibeke Strand,Peter Tugwell,Roy D. Altman,Kenneth D. Brandt,Maxime Dougados,Michel Lequesne +9 more
TL;DR: A consensus was reached by at least 90% of participants that the following 4 domains should be evaluated in future phase III trials of knee, hip, and hand OA: pain, physical function, patient global assessment, and, for studies of one year or longer, joint imaging.
Journal ArticleDOI
OMERACT-OARSI Initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited.
T. Pham,D. van der Heijde,Roy D. Altman,Jennifer J. Anderson,Nicholas Bellamy,Marc C. Hochberg,Lee S. Simon,Vibeke Strand,Thasia G. Woodworth,Maxime Dougados +9 more
TL;DR: This data driven and experts' opinion approach is the basis for proposing an optimal simplified set of responder criteria for OA clinical trials.